Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine

INDIANAPOLIS, Nov. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment of migraine with or...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news